Orexigen Therapeutics Inc. (NASDAQ:OREX) saw strong trading volume on Thursday . 149,571 shares changed hands during trading, an increase of 1% from the previous session’s volume of 148,472 shares.The stock last traded at $3.83 and had previously closed at $4.02.

Separately, Zacks Investment Research upgraded Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, July 11th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $2.04.

The firm’s market capitalization is $55.72 million. The firm has a 50-day moving average of $3.87 and a 200-day moving average of $5.79.

Orexigen Therapeutics (NASDAQ:OREX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by $0.26. During the same quarter in the prior year, the business posted ($0.18) earnings per share. The company earned $7.79 million during the quarter, compared to the consensus estimate of $6.88 million. The firm’s quarterly revenue was up 50.0% compared to the same quarter last year. On average, equities analysts expect that Orexigen Therapeutics Inc. will post ($6.37) EPS for the current fiscal year.

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.